CompletedNCT04366973
A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers
Observational studyAges 18+France
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Nice and 29 more locationsSee all locations and recruitment
Study information
Study start dateStarted: May 26, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 95
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Study phase
- Not clearly listed
- Locations
- France
- Age range
- Over 18 Years
- Official registry ID
- NCT04366973
- Official title
Show the full official title
New Care Pathways to Achieve HCV Elimination in the Community: Real-world Outcomes From HCV Infected Patients Treated in Addiction Centers in France
Recruitment & locations
CompletedNice · Valence · Bagnols-sur-Cèze
24 more locations
- Nîmes
- Bordeaux
- Montpellier
- Ploërmel
- Metz
- Saintes
- Lille
- Montauban
- Bron
- Antibes
- Bayonne
- Clermont-Ferrand
- Cognac
- Colmar
- Fontaine-lès-Dijon
- Le Coudray
- Limoges
- Marseille
- Mulhouse
- Nantes
- Paris
- Pau
- Strasbourg
- Bagneux
Questions about this study
Who is behind this study?
The study sponsor is AbbVie.
Who was this study for?
Listed age limits: from 18 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me